How do drug prices respond to a change from external to internal reference pricing? Evidence from a Danish regulatory reform

Arbeitspapier

We study the effects of a change in the way patient reimbursements are calculated on the prices of pharmaceuticals using quasi-experimental data for Denmark which switched from external (where reimbursements are based on prices of similar products in foreign countries) to internal reference pricing (where they are based on the cheapest domestic substitute). We analyze three therapeutic classes with different treatment durations and show that the reform led to substantial price decreases for our lifelong treatment and to less substantial price reductions for our medium duration treatment while we do not find significant effects on our acute treatment. Moreover, the reform did only affect generics and did not impact original products or parallel imports.

Object Details

• Language: Englisch

References and Relationships

• Bibliographic citation: Series: ZEW Discussion Papers ; No. 15-004

Classification and Topics

• Classification: Wirtschaft ; Health: Government Policy; Regulation; Public Health ; Single Equation Models; Single Variables: Panel Data Models; Spatio-temporal Models
• Subject: pharmaceutical markets ; regulation ; reference pricing ; treatment duration

Contributors, Places and Time

• Event: Geistige Schöpfung
• (who): Kaiser, Ulrich ; Mendez, Susan J.
• Event: Veröffentlichung
• (who): Zentrum für Europäische Wirtschaftsforschung (ZEW)
• (where): Mannheim
• (when): 2015

Further information

• Handle: http://hdl.handle.net/10419/106172
• URN: urn:nbn:de:bsz:180-madoc-380322
• Last update: 10.03.2025, 11:45 AM CET